Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative

January 12, 2010Press Releases

CHARLOTTESVILLE, Virginia, January 12 /PRNewswire/ — Biovista Inc. today announced that the U.S. Food and Drug Administration (FDA) has licensed its technology platform to help analyze, identify, and better understand the way certain drugs can cause harmful side effects. The FDA’s Office of Clinical Pharmacology, within the Center for Drug Evaluation and Research (CDER), will … Read More

Biovista Inc. Named Top Innovator in Life Sciences

December 16, 2009Press Releases

CHARLOTTESVILLE, Virginia, December 16 /PRNewswire/ — Biovista Inc. today announced that it was awarded the 2009 Top Innovator Presentation Award in Healthcare, at the 2009 New England Venture Summit, held on December 8th at Dedham, MA. The award, which recognizes cutting edge private companies driving the future of innovation, was granted to Biovista who competed … Read More

TIF awards contract to Biovista for the installation of the JAnaemia patient record management system

December 1, 2009Press Releases

CHARLOTTESVILLE, Virginia and ATHENS, Greeece, December 1 /PRNewswire/ — Biovista Inc. today announced the signing of a new collaboration agreement with the Thalassaemia International Federation (TIF) for the installation and support of its JAnaemia patient record management system. JAnaemia, which has been customized, in this case for beta thalassaemia patients, will be initially installed at … Read More

Biovista announces positive efficacy results in a pre-clinical trial of BVA-201 for Multiple Sclerosis

September 9, 2009Press Releases

CHARLOTTESVILLE, Virginia, September 9 /PRNewswire/ — Biovista Inc. today announced that BVA-201, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is an existing drug that Biovista repositioned in MS and is aimed at neuroprotection. It was shown to have both … Read More